Regeneron Pharmaceuticals Inc.

02/08/2025 | Press release | Distributed by Public on 02/08/2025 16:40

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.